Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 21;13(21):5274.
doi: 10.3390/cancers13215274.

Interaction of Opioids with TLR4-Mechanisms and Ramifications

Affiliations
Review

Interaction of Opioids with TLR4-Mechanisms and Ramifications

Mai Mahmoud Gabr et al. Cancers (Basel). .

Abstract

The innate immune receptor toll-like receptor 4 (TLR4) is known as a sensor for the gram-negative bacterial cell wall component lipopolysaccharide (LPS). TLR4 activation leads to a strong pro-inflammatory response in macrophages; however, it is also recognised to play a key role in cancer. Recent studies of the opioid receptor (OR)-independent actions of opioids have identified that TLR4 can respond to opioids. Opioids are reported to weakly activate TLR4, but to significantly inhibit LPS-induced TLR4 activation. The action of opioids at TLR4 is suggested to be non-stereoselective, this is because OR-inactive (+)-isomers of opioids have been shown to activate or to inhibit TLR4 signalling, although there is some controversy in the literature. While some opioids can bind to the lipopolysaccharide (LPS)-binding cleft of the Myeloid Differentiation factor 2 (MD-2) co-receptor, pharmacological characterisation of the inhibition of opioids on LPS activation of TLR4 indicates a noncompetitive mechanism. In addition to a direct interaction at the receptor, opioids affect NF-κB activation downstream of both TLR4 and opioid receptors and modulate TLR4 expression, leading to a range of in vivo outcomes. Here, we review the literature reporting the activity of opioids at TLR4, its proposed mechanism(s), and the complex functional consequences of this interaction.

Keywords: lipopolysaccharide; morphine; opioids; toll-like receptor 4.

PubMed Disclaimer

Conflict of interest statement

M.M.G., I.S., J.A.M., B.P.R., P.N.S. and M.-O.P. declare no conflict of interest. Markus W. Hollmann has received research funding from CSL Behring, ZonMw, the Society of Cardiovasular Anesthesiologists (SCA) and the European Association of Cardiothoracic Anaesthesiology (EACTA), and has received compensation from Eurocept Pharmaceuticals, BV, and IDD for services as a consultant. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Signalling pathways elicited by LPS activation of TLR4.

References

    1. García Bueno B., Caso J.R., Madrigal J.L.M., Leza J.C. Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseases. Neurosci. Biobehav. Rev. 2016;64:134–147. doi: 10.1016/j.neubiorev.2016.02.013. - DOI - PubMed
    1. Pandey N., Chauhan A., Jain N. TLR4 Polymorphisms and Expression in Solid Cancers. Mol. Diagn. Ther. 2018;22:683–702. doi: 10.1007/s40291-018-0361-9. - DOI - PubMed
    1. Vijay K. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future. Int. Immunopharmacol. 2018;59:391–412. doi: 10.1016/j.intimp.2018.03.002. - DOI - PMC - PubMed
    1. Alexander C., Rietschel E.T. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2001;7:167–202. doi: 10.1179/096805101101532675. - DOI - PubMed
    1. De Nardo D. Toll-like receptors: Activation, signalling and transcriptional modulation. Cytokine. 2015;74:181–189. doi: 10.1016/j.cyto.2015.02.025. - DOI - PubMed

LinkOut - more resources